Severe Late-Onset Drug-Induced Immune Thrombocytopenia Following IFN <i>β</i>-1a Treatment: A Case Report of a 52-Year-Old Woman with Relapse-Remitting Multiple Sclerosis

<div>Platelet count at baseline (2 months before), since the last interferon <i>β</i>-1a injection before the occurrence of petechial lesions (IFN<i>β</i>-1a, D0) and upon rechallenge (D14), and their evolution with subsequent treatments. Prednisone (PDN) is only shown when 1 mg/kg has been initiated. Two administrations of intravenous immunoglobulins (IVIG, 2 g/kg total dose) were performed.</div>

Case Reports in Hematology

fig1

Figure 1

Figure 1: Severe Late-Onset Drug-Induced Immune Thrombocytopenia Following IFN <i>β</i>-1a Treatment: A Case Report of a 52-Year-Old Woman with Relapse-Remitting Multiple Sclerosis 

Figure 1 | Severe Late-Onset Drug-Induced Immune Thrombocytopenia Following IFN β-1a Treatment: A Case Report of a 52-Year-Old Woman with Relapse-Remitting Multiple Sclerosis 